Comparing Black Titan (BTTC) & Its Rivals

Black Titan (NASDAQ:BTTC) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it compare to its rivals? We will compare Black Titan to similar businesses based on the strength of its risk, analyst recommendations, valuation, institutional ownership, dividends, earnings and profitability.

Insider & Institutional Ownership

57.5% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 53.7% of Black Titan shares are held by company insiders. Comparatively, 20.5% of shares of all “Services – Computer Programming And Data Processing” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Black Titan and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	98	197	218	12	2.27

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 108.12%. Given Black Titan’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Black Titan has less favorable growth aspects than its rivals.

Profitability

This table compares Black Titan and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-51.08%	-912.69%	-63.05%

Volatility and Risk

Black Titan has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s rivals have a beta of 0.68, meaning that their average stock price is 32% less volatile than the S&P 500.

Valuation and Earnings

This table compares Black Titan and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.62
Black Titan Competitors	$223.24 million	-$53.25 million	-11.04

Black Titan’s rivals have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Black Titan rivals beat Black Titan on 7 of the 12 factors compared.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.